RT Journal Article SR Electronic T1 Predicting Time to Diabetes Diagnosis Using Random Survival Forests JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.02.03.24302304 DO 10.1101/2024.02.03.24302304 A1 Saha, Priyonto A1 Marouf, Yacine A1 Pozzebon, Hunter A1 Guergachi, Aziz A1 Keshavjee, Karim A1 Noaeen, Mohammad A1 Shakeri, Zahra YR 2024 UL http://medrxiv.org/content/early/2024/02/07/2024.02.03.24302304.abstract AB Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder with increasing population incidence. However, T2DM takes years to develop, allowing onset prediction and prevention to be a clinically effective treatment strategy. In this study we propose and assess a novel approach to diabetes prediction which integrates a specialized extension of the random forest algorithm known as random survival forest (RSF). Rather than predicting a binary outcome, this machine learning model incorporates survival analysis methodology to predict the time until a patient will receive a diabetes diagnosis if their current lifestyle is maintained. We trained a baseline model on 7,704 electronic medical records from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) with 14 biomarker and comorbidity features across different measurement dates. Although tuning parameters were purposefully chosen for quick training rather than for predictive performance, our model exceeded expectations with a concordance index of 0.84. Thus, RSF models have been shown to produce accurate timelines of diabetes onset trajectory, providing patients with quantifiable and relatable risks that are easy to understand. The results of our study have substantial implications for advancing machine learning in clinical decision support and patient outcome predictions, emphasizing the role of innovative models in improving predictive accuracy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data used are available online at https://cpcssn.ca/ website upon reasonable request.